{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T01:29:04Z","timestamp":1691803744262},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2007,8,19]],"date-time":"2007-08-19T00:00:00Z","timestamp":1187481600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1007\/s11912-007-0051-y","type":"journal-article","created":{"date-parts":[[2007,8,18]],"date-time":"2007-08-18T11:06:11Z","timestamp":1187435171000},"page":"378-383","source":"Crossref","is-referenced-by-count":2,"title":["Rituximab maintenance in indolent lymphoma: Indications and controversies"],"prefix":"10.1007","volume":"9","author":[{"given":"Marinus H.J.","family":"van Oers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,8,19]]},"reference":[{"key":"51_CR1","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1200\/JCO.1995.13.1.140","volume":"13","author":"P.W. Johnson","year":"1995","unstructured":"Johnson PW, Rohatiner AZ, Whelan JS, et al.: Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995, 13:140\u2013147.","journal-title":"J Clin Oncol"},{"key":"51_CR2","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1200\/JCO.1995.13.7.1726","volume":"13","author":"A.R. Yuen","year":"1995","unstructured":"Yuen AR, Kamel OW, Halpern J, Horning S: Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol 1995, 13:1726\u20131733.","journal-title":"J Clin Oncol"},{"key":"51_CR3","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/1097-0142(19870715)60:2<156::AID-CNCR2820600205>3.0.CO;2-K","volume":"60","author":"E.Z. Ezdinli","year":"1987","unstructured":"Ezdinli EZ, Harrington DP, Kucuk O, et al.: The effect of intensive intermittent maintenance therapy in advanced low-grade non-Hodgkin\u2019s lymphoma. Cancer 1987, 60:156\u2013160.","journal-title":"Cancer"},{"key":"51_CR4","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/1097-0142(19880201)61:3<441::AID-CNCR2820610306>3.0.CO;2-N","volume":"61","author":"W.P. Steward","year":"1988","unstructured":"Steward WP, Crowther D, McWilliam LJ, et al.: Maintenance chlorambucil after CVP in the management of advanced-stage, low-grade histologic type non-Hodgkin\u2019s lymphoma. A randomized prospective study with an assessment of prognostic factors. Cancer 1988, 61:441\u2013447.","journal-title":"Cancer"},{"key":"51_CR5","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3109\/10428199609052435","volume":"20","author":"A. Aviles","year":"1996","unstructured":"Aviles A, Duque G, Talavera A, Guzman R: Interferon alpha 2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival. Leuk Lymphoma 1996, 20:495\u2013499.","journal-title":"Leuk Lymphoma"},{"key":"51_CR6","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1200\/JCO.1998.16.4.1538","volume":"16","author":"R. Arranz","year":"1998","unstructured":"Arranz R, Garcia-Alfonso P, Sobrino P, et al.: Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin\u2019s lymphoma: results from a prospective, multicenter trial with double randomization. J Clin Oncol 1998, 16:1538\u20131546.","journal-title":"J Clin Oncol"},{"key":"51_CR7","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1200\/JCO.2000.18.10.2010","volume":"18","author":"R.I. Fisher","year":"2000","unstructured":"Fisher RI, Dana BW, LeBlanc M, et al.: Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin\u2019s lymphoma: results of the Southwest Oncology Group randomized Phase III study 8809. J Clin Oncol 2000, 18:2010\u20132016.","journal-title":"J Clin Oncol"},{"key":"51_CR8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1200\/JCO.1998.16.1.41","volume":"16","author":"A. Hagenbeek","year":"1998","unstructured":"Hagenbeek A, Carde P, Meerwaldt JH,, et al.: Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin\u2019s lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1998, 16:41\u201347.","journal-title":"J Clin Oncol"},{"key":"51_CR9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1054\/bjoc.2001.1822","volume":"85","author":"A. Rohatiner","year":"2001","unstructured":"Rohatiner A, Radford J, Deakin D, et al.: A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma. Br J Cancer 2001, 85:29\u201335.","journal-title":"Br J Cancer"},{"key":"51_CR10","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1200\/JCO.2005.06.146","volume":"23","author":"A.Z. Rohatiner","year":"2005","unstructured":"Rohatiner AZ, Gregory WM, Peterson B, et al.: Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 2005, 23:2215\u20132223.","journal-title":"J Clin Oncol"},{"key":"51_CR11","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P. McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-Lopez AJ, Link BK, et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825\u20132833.","journal-title":"J Clin Oncol"},{"key":"51_CR12","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1046\/j.1365-2141.1999.01608.x","volume":"106","author":"K. Schmitz","year":"1999","unstructured":"Schmitz K, Brugger W, Weiss B, et al.: Clonal selection of CD20-negative non-Hodgkin\u2019s lymphoma cells after treatment with anti-CD20 antibody rituximab. Br J Haematol 1999, 106:571\u2013572.","journal-title":"Br J Haematol"},{"key":"51_CR13","first-page":"611","volume":"5","author":"T.A. Davis","year":"1999","unstructured":"Davis TA, Czerwinski DK, Levy R: Therapy of B-cell lymphoma with anti-CD20 antibodies can result in loss of CD20 antigen expression. Clin Cancer Res 1999, 5:611\u2013615.","journal-title":"Clin Cancer Res"},{"key":"51_CR14","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","volume":"20","author":"J.D. Hainsworth","year":"2002","unstructured":"Hainsworth JD, Litchy S, Burris HA III, et al.: Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin\u2019s lymphoma. J Clin Oncol 2002, 20:4261\u20134267.","journal-title":"J Clin Oncol"},{"key":"51_CR15","first-page":"411a","volume":"102","author":"J.D. Hainsworth","year":"2003","unstructured":"Hainsworth JD, Litchy S, Morrissey L, et al.: Rituximab as first-line and maintenance therapy for indolent non-Hodgkin\u2019s lymphoma (NHL): long-term follow-up of a Minnie Pearl Cancer Research Network Phase II trial [abstract]. Blood 2003, 102:411a\u2013412a.","journal-title":"Blood"},{"key":"51_CR16","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","volume":"103","author":"M. Ghielmini","year":"2004","unstructured":"Ghielmini M, Schmitz S-FH, Cogliatti SB, et al.: Prolonged treatment with rituximab in patients with follicular lymphoma a significantly increases event-free survival and response duration compared with the standard weekly x4 schedule. Blood 2004, 103:4416\u20134423.","journal-title":"Blood"},{"issue":"Suppl","key":"51_CR17","doi-asserted-by":"crossref","first-page":"6502","DOI":"10.1200\/jco.2004.22.14_suppl.6502","volume":"22","author":"H.S. Hochster","year":"2004","unstructured":"Hochster HS, Weller E, Ryan T, et al.: Results of E1496: a phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL) [abstract]. J Clin Oncol 2004, 22(Suppl):6502.","journal-title":"J Clin Oncol"},{"key":"51_CR18","doi-asserted-by":"crossref","unstructured":"Hochster HS, Weller E, Gascoyne RD, et al.: Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B [abstract]. Blood 2005, 106:106a.","DOI":"10.1182\/blood.V106.11.349.349"},{"key":"51_CR19","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","volume":"108","author":"M.H.J. Oers van","year":"2006","unstructured":"van Oers MHJ, Klasa R, Marcus RE, et al.: Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin\u2019s lymphoma, both in patients with and without rituximab during induction: results of a prospective randomized phase III intergroup trial. Blood 2006, 108:3295\u20133301.","journal-title":"Blood"},{"key":"51_CR20","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"R. Forstpointner","year":"2004","unstructured":"Forstpointner R, Dreyling M, Repp R, et al.: The addition of rituximab to a combination of fludarabine, cyclophosphamide and mitoxantrone (FCM) significantly prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphoma: results of a prospective randomized study of the German Low Grade Lymphoma Study Group. Blood 2004, 104:3064\u20133071.","journal-title":"Blood"},{"issue":"Suppl","key":"51_CR21","doi-asserted-by":"crossref","first-page":"6528","DOI":"10.1200\/jco.2005.23.16_suppl.6528","volume":"23","author":"M.H. Dreyling","year":"2005","unstructured":"Dreyling MH, Forstpointner R, Ludwig W, et al.: Combined immuno-chemotherapy (R-FCM) results in superior remission rates and overall survival in recurrent follicular and mantle cell lymphoma: follow-up of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG) [abstract]. J Clin Oncol 2005, 23(Suppl):6528.","journal-title":"J Clin Oncol"},{"key":"51_CR22","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"R. Forstpointner","year":"2006","unstructured":"Forstpointner R, Unterhalt M, Dreyling M, et al.: Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) in patients with relapsed and refractory follicular and mantle cell lymphomas-results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006, 108:4003\u20134008.","journal-title":"Blood"},{"key":"51_CR23","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1182\/blood.V108.11.2769.2769","volume":"108","author":"M.H. Dreyling","year":"2006","unstructured":"Dreyling MH, Forstpointner R, Boeck H, et al.: Combined immuno-chemotherapy followed by rituximab maintenance is an effective salvage treatment after prior rituximab containing therapy: results of a GLSG-subgroup analysis in patients with relapsed indolent lymphoma [abstract]. Blood 2006, 108:2769.","journal-title":"Blood"},{"key":"51_CR24","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","volume":"23","author":"J.D. Hainsworth","year":"2005","unstructured":"Hainsworth JD, Litchy S, Shaffer DW, et al.: Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin\u2019s lymphoma: a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005, 23:1088\u20131095.","journal-title":"J Clin Oncol"},{"key":"51_CR25","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.1182\/blood.V108.11.4723.4723","volume":"108","author":"J.D. Hainsworth","year":"2006","unstructured":"Hainsworth JD, Meng C, Spigel DR, et al.: Long-term follow-up of patients with follicular lymphoma (FL) treated with two years of maintenance rituximab: response to rituximab retreatment at progression [abstract]. Blood 2006, 108:4723.","journal-title":"Blood"},{"key":"51_CR26","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1023\/A:1008416911099","volume":"9","author":"N.L. Berinstein","year":"1998","unstructured":"Berinstein NL, Grillo-Lopez AJ, et al.: Association of serum rituximab (IDEC-C2B8) concentration and antitumor response in the treatment of recurrent low-grade or follicular non-Hodgkin\u2019s lymphoma. Ann Oncol 1998, 9:995\u20131001.","journal-title":"Ann Oncol"},{"key":"51_CR27","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1200\/JCO.2005.12.171","volume":"23","author":"L.N. Gordan","year":"2005","unstructured":"Gordan LN, Grow WB, Pusateri A, et al.: Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 2005, 23:1096\u20131102.","journal-title":"J Clin Oncol"},{"key":"51_CR28","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","volume":"31","author":"E. Kimby","year":"2005","unstructured":"Kimby E: Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005, 31:456\u2013473.","journal-title":"Cancer Treat Rev"},{"issue":"Suppl1","key":"51_CR29","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1023\/A:1008301432453","volume":"11","author":"M. Ghielmini","year":"2000","unstructured":"Ghielmini M, Schmitz SF, Burki K, et al.: The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2000, 11(Suppl 1):123\u2013126.","journal-title":"Ann Oncol"},{"key":"51_CR30","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.clon.2005.11.015","volume":"18","author":"G.B. Fogarty","year":"2006","unstructured":"Fogarty GB, Bayne M, Bedford P, et al.: Three cases of activation of cutaneous squamous-cell carcinoma during treatment with prolonged administration of rituximab. Clin Oncol (R Coll Radiol) 2006, 18:155\u2013156.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"Suppl5","key":"51_CR31","first-page":"v51","volume":"16","author":"M. Herold","year":"2005","unstructured":"Herold M, Pasold R, Srock S, et al.: Rituximab plus mitoxantrone, chlorambucil, prednisolone (R-MCP) is superior to MCP alone in advanced indolent and follicular lymphoma \u2014 results of a Phase III study (OSHO39) [abstract]. Ann Oncol 2005, 16(Suppl 5):v51\u2013v52.","journal-title":"Ann Oncol"},{"key":"51_CR32","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W. Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M, et al.: Front-line therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome of patients with advanced-stage follicular lymphomas as compared to CHOP alone, results of a prospective randomised study of the German Low-Grade Lymphoma Study Group (GLSG). Blood 2005, 106:3725\u20133732.","journal-title":"Blood"},{"key":"51_CR33","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","volume":"105","author":"R. Marcus","year":"2005","unstructured":"Marcus R, Imrie K, Belch A, et al.: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005, 105:1417\u20131423.","journal-title":"Blood"},{"key":"51_CR34","doi-asserted-by":"crossref","first-page":"49a","DOI":"10.1182\/blood.V104.11.160.160","volume":"104","author":"G. Salles","year":"2004","unstructured":"Salles G, Foussard C, Mounier N, et al.: Rituximab added to alfa IFN-CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: first analysis of the GELA-GOELAMS FL-2000 randomized trial in 359 patients [abstract]. Blood 2004, 104:49a\u201350a.","journal-title":"Blood"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-007-0051-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-007-0051-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-007-0051-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T23:55:32Z","timestamp":1587858932000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-007-0051-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,19]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["51"],"URL":"https:\/\/doi.org\/10.1007\/s11912-007-0051-y","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,19]]}}}